A Meta-Analysis and Meta-Regression of the Efficacy, Toxicity, and Quality of Life Outcomes Following Prostate-Specific Membrane Antigen Radioligand Therapy Utilising Lutetium-177 and Actinium-225 in Metastatic Prostate Cancer
Open Access
- 25 September 2024
- journal article
- research article
- Published by Elsevier in European Urology
- Vol. 87 (4) , 398-408
Abstract
No abstract availableKeywords
Funding Information
- Prostate Cancer UK (IMM19-009)
- Tri-Service General Hospital
This publication has 39 references indexed in Scilit:
- Validation of Prognostic and Predictive Models for Therapeutic Response in Patients Treated with [177Lu]Lu-PSMA-617 Versus Cabazitaxel for Metastatic Castration-resistant Prostate Cancer (TheraP): A Post Hoc Analysis from a Randomised, Open-label, Phase 2 TrialEuropean Urology Oncology, 2024
- Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteriaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2022
- Hematologic toxicity profile and efficacy of [225Ac]Ac-PSMA-617 α-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2022
- 177Lu‐PSMA radioligand therapy effectiveness in metastatic castration‐resistant prostate cancer: An updated systematic review and meta‐analysisThe Prostate, 2022
- Real-World Data Analysis of Efficacy and Survival After Lutetium-177 Labelled PSMA Ligand Therapy in Metastatic Castration-Resistant Prostate CancerTargeted Oncology, 2021
- E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PETEuropean Journal of Nuclear Medicine and Molecular Imaging, 2021
- Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2020
- The value of tumor markers in men with metastatic prostate cancer undergoing [177Lu]Lu‐PSMA therapyThe Prostate, 2019
- PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survivalEuropean Journal of Nuclear Medicine and Molecular Imaging, 2017
- Random effects meta‐analysis: Coverage performance of 95% confidence and prediction intervals following REML estimationStatistics in Medicine, 2016